| review article | Q7318358 |
| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P356 | DOI | 10.1016/J.NUMECD.2015.06.005 |
| P8608 | Fatcat ID | release_7rbvu4zffjh55inkoihveq7y4u |
| P3181 | OpenCitations bibliographic resource ID | 2951658 |
| P698 | PubMed publication ID | 26232910 |
| P5875 | ResearchGate publication ID | 279312816 |
| P2093 | author name string | S Del Prato | |
| M Niemeyer | |||
| M Diamant | |||
| D Russell-Jones | |||
| M-A Gall | |||
| P2860 | cites work | Clinical and socio-economic correlates of quality of life and treatment satisfaction in patients with type 2 diabetes | Q46616745 |
| Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes | Q49174475 | ||
| Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes | Q84440683 | ||
| Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). | Q22241288 | ||
| Ligand-controlled assembly of hexamers, dihexamers, and linear multihexamer structures by the engineered acylated insulin degludec | Q27683621 | ||
| Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort | Q31101983 | ||
| Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority tria | Q34269828 | ||
| Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority tria | Q34269834 | ||
| Clinical Experience with Insulin Glargine in Type 1 Diabetes | Q34296834 | ||
| Self-reported non-severe hypoglycaemic events in Europe | Q34516215 | ||
| Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials | Q34726423 | ||
| A comparison of health-related quality of life (health utility) between insulin degludec and insulin glargine: a meta-analysis of phase 3 trials. | Q34981168 | ||
| Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study | Q36208628 | ||
| Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long) | Q36426912 | ||
| Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir | Q36682344 | ||
| The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in i | Q36720304 | ||
| Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension | Q36730246 | ||
| Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-ta | Q37106509 | ||
| Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials | Q37119978 | ||
| Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people | Q37278100 | ||
| Addressing barriers to initiation of insulin in patients with type 2 diabetes | Q37731624 | ||
| Insulin degludec and insulin degludec/insulin aspart: a review of their use in the management of diabetes mellitus | Q38101891 | ||
| Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. | Q42240405 | ||
| Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study | Q42624054 | ||
| Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes. | Q42664001 | ||
| Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes | Q44909481 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hypoglycemia | Q202758 |
| insulin glargine | Q417317 | ||
| meta-analysis | Q815382 | ||
| preproinsulin | Q7240673 | ||
| P304 | page(s) | 898-905 | |
| P577 | publication date | 2015-10-01 | |
| P1433 | published in | Nutrition, Metabolism, and Cardiovascular Diseases | Q2734631 |
| P1476 | title | Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials | |
| P478 | volume | 25 |
| Q47176512 | Antihyperglycemic Agent Therapy for Adult Patients with Type 2 Diabetes Mellitus 2017: A Position Statement of the Korean Diabetes Association |
| Q47094226 | Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association |
| Q91787082 | Clinical implications of prolonged hyperglycaemia before basal insulin initiation in type 2 diabetes patients: An electronic medical record database analysis |
| Q89230569 | Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study |
| Q52605864 | Efficacy and Safety of Insulin Glargine 300 U/mL versus 100 U/mL in Diabetes Mellitus: A Comprehensive Review of the Literature. |
| Q90456535 | Exposure to insulin degludec during pregnancy: report of a small series and review of the literature |
| Q38916256 | Insulin degludec + liraglutide: a complementary combination |
| Q48306120 | Insulin degludec in the first trimester of pregnancy: Report of two cases. |
| Q28074690 | Insulin glargine 300 U/mL in the management of diabetes: clinical utility and patient perspectives |
| Q57026285 | Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) |
| Q56979722 | Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) |
| Q64072341 | Optimal regulation of blood glucose level in Type I diabetes using insulin and glucagon |
| Q47259503 | Real-world evidence on clinical and economic outcomes of switching to insulin glargine 300 Units/mL vs other basal insulins in patients with type 2 diabetes on basal insulin. |
| Q37538487 | Real-world medication persistence and outcomes associated with basal insulin and glucagon-like peptide 1 receptor agonist free-dose combination therapy in patients with type 2 diabetes in the US. |
| Q90402553 | Second-Generation Insulin Analogues - a Review of Recent Real-World Data and Forthcoming Head-to-Head Comparisons |
| Q93167299 | Successful Outcomes with Insulin Degludec in Pregnancy: A Case Series |
| Q90359481 | Suitable Use of Injectable Agents to Overcome Hypoglycemia Risk, Barriers, and Clinical Inertia in Community-Dwelling Older Adults with Type 2 Diabetes Mellitus |
| Q57281197 | Time-action profiles of insulin degludec in healthy dogs and its effects on glycemic control in diabetic dogs |
| Q99560824 | Understanding the Clinical Profile of Insulin Degludec, the Latest Basal Insulin Approved for Use in Canada: a Narrative Review |
Search more.